Symptoms : dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. Overdose of Ulkavis drug®caused by prolonged doses exceeding the recommended ones can lead to impaired renal function. These symptoms are completely reversible when the drug is canceled by Ulkavis®.
Treatment: gastric lavage, the purpose of activated carbon and salt laxatives. Further treatment should be symptomatic. In case of impaired renal function, which is accompanied by a high concentration of vismut in the blood plasma, it is possible to prescribe chelate converters (penicillamine, sodium dimerkaptopropan sulfonate). In the event of a pronounced violation of the function of the kidneys, hemodialysis is shown.
individual intolerance of the drug ;
severe renal failure (Cl creatinine less than 30 ml / min) ;
pregnancy;
period of breastfeeding ;
childhood up to 4 years.
Within half an hour before and after taking the drug Ulkavis® it is not recommended to use other drugs inside, as well as eating and liquid, in particular antacids, milk, fruits and fruit juices. This is due to the fact that they can simultaneously take inward the effectiveness of Ulkavis®.
Simultaneous use of the drug Ulkavis® with tetracycline reduces the absorption of the latter.
Round, slightly double-branded tablets coated with a white or almost white film shell with a chamomel.
View of the break : rough white mass with a shell of white or almost white.
From the digestive system : the appearance of nausea, vomiting, more frequent stool, constipation is possible. These phenomena are not hazardous to health and are temporary.
Allergic reactions : skin rash, skin itching.
With prolonged use in high doses, the development of encephalopathy associated with the accumulation of vismut in the central nervous system is possible.
Uncounter.
The drug is Ulkavis® should not be used for more than 8 weeks. It is also not recommended to exceed the established per diem doses for adults and children during treatment. During treatment with Ulkavis® other drugs containing bismuth should not be used. At the end of course treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 μg / L, and intoxication is observed only at a concentration in the blood plasma above 100 μg / L. When using the drug Ulkavis® coloring of feces in dark color is possible due to the formation of a sulfide of the vismut. Sometimes there is a slight darkening of the language.
peptic ulcer of the stomach and duodenum in the phase of exacerbation, including.h. associated with Helicobacter pylori;
chronic gastritis and gastroduodenitis in the phase of exacerbation, including.h. associated with Helicobacter pylori;
irritable bowel syndrome, occurring mainly with symptoms of diarrhea ;
functional dyspepsia not related to organic diseases of the gastrointestinal tract.
Antificial agent with bactericidal activity in relation Helicobacter pylori It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble vismuta oxychloride and citrate are precipitated, chelate compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosion. Increasing the synthesis of PGE, the formation of mucus and the secretion of hydrocarbonate, stimulates the activity of cytoprotectory mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsiin, hydrochloric acid, enzymes and bile acid salts. It leads to the accumulation of the epidermal growth factor in the defect zone. Reduces pepsin activity.
The vismut subcitrate is practically not absorbed from the LCD. It is excreted mainly through the intestines with feces. A small amount of vismut, received in the blood plasma, is excreted by the kidneys.
Keep out of the reach of children.
Shelf life of the drug Ulkavis®2 years.Do not apply after the expiration date indicated on the package.
| Tablets coated with a film shell | 1 table. |
| active substance : | |
| the tricalium of dicitrate is in shape | 303.03 mg |
| (equivalent to a vismut oxide of 120 mg) | |
| auxiliary substances : corn starch - 72.17 mg; obedient K30 - 18 mg; potassium polykrilin - 23.8 mg; macrogol 6000 - 6 mg; magnesium stearat - 2 mg | |
| film shell : Opadry II transparent (polyvinyl alcohol - 4.505 mg, macrogol 4000 - 2.295 mg; talcum powder - 1.7 mg) - 8.5 mg; titanium dioxide (E171) - 1.5 mg |
Tablets coated with a film shell, 120 mg. 14 tablets each. in a blister of combined material (OPA / Al / PVC) and aluminum foil.
For 2, 4 and 8 bl. (bl. 14 tablets each.) put in a cardboard pack.
The use of the drug Ulkavis® during pregnancy and during breastfeeding, contraindicated.
Inside, 30 minutes before eating, with a little water.
Adults and children over 12 years old drug Ulkavis® assigned 1 table. 4 times a day for 30 minutes before eating and at night or 2 tablets each. 2 times a day.
Children from 8 to 12 years old are the drug Ulkavis® assigned 1 table. 2 times a day; from 4 to 8 years are assigned at a dose of 8 mg / kg / day, depending on the body weight of the child, 1–2 tablets each./ day (respectively, in 1-2 doses per day). In this case, the daily dose should be closest to the estimated dose (8 mg / kg / day).
The duration of the course of treatment is 4–8 weeks. Over the next 8 weeks, drugs containing bismuth should not be used.
For eradaptation Helicobacter pylori it is advisable to use the drug Ulkavis® in combination with other antibacterial agents with antichelicobacterial activity (as recommended by the doctor).
